Grounded in nature, authored by AI
Emeryville, CA
Joined September 2022
- Tweets186
- Following0
- Followers4.1K
- Likes39
Profluent@ProfluentBio
Aug 12United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
Stephen Nayfach, our Head of Bioinformatics and Platform R&D, is at @CSHL this week for the Genome Engineering: CRISPR Frontiers event. Find him and say hi if you're there! 👋
He's giving a talk on using our AI models to design CRISPR-Cas9 variants for base editing ("Programming PAM Specificity for Mutation-Specific Base Editor Design") and also chairing the session "CRISPR Technologies I"
Profluent@ProfluentBio
Jul 30United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
The Profluent team is heading to Summer RosettaCon next week! Find @jeffruffolo, @richardwshuai, @ShiakiMinami, and Alex Hoffnagle and say hi 👋
You can hear Richard talk about E1, our encoder model, on Thur at 1:30pm (“E1: Retrieval-Augmented Protein Encoders for Fitness and Structure Prediction”) and Alex share his work on our AI-designed base editors on Mon at 7:30pm (“Design of Programmable Base Editors with Protein Language Models”).
Profluent@ProfluentBio
Jul 9United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
A suite of AI-designed base editors, all from one scaffold. The only piece unique to each patient is the guide RNA.
That's the shift AI unlocks: rare disease moves from 'one drug at a time' to a platform, built to bring cost down and reach more patients.
More on our work with GEMMABio, now backed by @ARPA_H's THRIVE program, below.
Profluent@ProfluentBio
Jun 26United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
We're still in the GPT 1.5 era of AI × biology
The early models already work (signal: our $2.25B Lilly partnership) but we're nowhere near the ceiling
We're speedrunning to GPT 5 as fast as we can
@thisismadani with @nathanbenaich @airstreet
it's been a huge few weeks for ai in bio: a $2.25b @profluentbio x @elilillyandco deal on ai-designed gene editors, verve's base-editing data, new scaling results on protein models from @czbiohub, @isomorphiclabs' haul.
@thisismadani and i recorded a pod diving into all of it
we get into taking biology from discovery to design, sequence-first vs structure-first, and why he calls this the "gpt-1.5 era" of biology...
enjoy!
Profluent@ProfluentBio
Jun 25United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
Biology is no less complex than text and (in our biased opinion) way more impactful. Yet a fraction of the world's AI talent and compute is pointed at it.
The field is wildly undersaturated.
Watch @thisismadani chat with @nathanbenaich @airstreetcapital about the opportunity.
it's been a huge few weeks for ai in bio: a $2.25b @profluentbio x @elilillyandco deal on ai-designed gene editors, verve's base-editing data, new scaling results on protein models from @czbiohub, @isomorphiclabs' haul.
@thisismadani and i recorded a pod diving into all of it
we get into taking biology from discovery to design, sequence-first vs structure-first, and why he calls this the "gpt-1.5 era" of biology...
enjoy!
Profluent@ProfluentBio
Jun 24United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
OpenCRISPR was the first demonstration that AI could design a genome editor from scratch. We used our AI model to build a protein that doesn't exist in nature for a specific function and it worked.
Watch @thisismadani chat with @nathanbenaich @airstreetcapital about where we’ve gone from there (and where we’re going)
it's been a huge few weeks for ai in bio: a $2.25b @profluentbio x @elilillyandco deal on ai-designed gene editors, verve's base-editing data, new scaling results on protein models from @czbiohub, @isomorphiclabs' haul.
@thisismadani and i recorded a pod diving into all of it
we get into taking biology from discovery to design, sequence-first vs structure-first, and why he calls this the "gpt-1.5 era" of biology...
enjoy!
Profluent@ProfluentBio
Jun 23United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
Our partnership with Eli Lilly carries up to $2.25B in milestones. The bigger story is the unlock behind it: large gene insertion, a problem AI makes solvable for the first time.
Watch @thisismadani in conversation with @nathanbenaich @airstreet.
it's been a huge few weeks for ai in bio: a $2.25b @profluentbio x @elilillyandco deal on ai-designed gene editors, verve's base-editing data, new scaling results on protein models from @czbiohub, @isomorphiclabs' haul.
@thisismadani and i recorded a pod diving into all of it
we get into taking biology from discovery to design, sequence-first vs structure-first, and why he calls this the "gpt-1.5 era" of biology...
enjoy!
Profluent@ProfluentBio
May 14United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
At PEGS Boston? Don't miss our Lead Protein Design Scientist Jeliazko Jeliazkov presenting "Designing Optimal Proteins at Scale"
Generating proteins that are simultaneously optimal across many properties (affinity, stability, developability, and beyond) is a hard problem. Jeli's sharing our work on alignment of our foundational AI models as a path to multi-parameter protein optimization, with applications from gene editors to antibodies.
Interested in learning more about our multi-parameter optimization work? Shoot us a DM.
Profluent@ProfluentBio
May 14United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
We're at @ASGCTherapy today sharing something we've been heads down building: using our AI models to scale base editing for personalized medicine.
The gap between what's theoretically correctable and what we can actually fix today is huge. We think AI can close that gap.
Not there? Peter Cameron, our SVP of Gene Editing, breaks it down here. Interested in learning more? Shoot us a DM.
Profluent@ProfluentBio
Apr 28United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
Today we announced a landmark partnership with @EliLillyandCo to use our AI models to design recombinases for genetic medicine—a collaboration valued at up to $2.25 billion before royalties.
The goal: use Profluent's AI models to design recombinase editors capable of inserting long stretches of DNA at precise locations in the genome.
Read the press release for more: businesswire.com/news/home/2…
